The Munich Biotech Cluster m4 Approach towards Personalised Medicine
-
Upload
eurobioforum -
Category
Business
-
view
574 -
download
2
description
Transcript of The Munich Biotech Cluster m4 Approach towards Personalised Medicine
![Page 1: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/1.jpg)
www.m4.de
The Munich Biotech Cluster m4 Approach
towards Personalized Medicine"
Horst Domdey BioM
![Page 2: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/2.jpg)
www.m4.de
BioM – Partner for Sustainable Innovation
• Scouting & Incubation • Start-up Consulting • Funding
Academia
Big Pharma
• Partnering
• Seminars & Workshops
• Networking
• Events
SME • Funding
• Partnering
• Business Development
• Networking
• Professional Training
• Events
www.bio-m.org
![Page 3: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/3.jpg)
www.m4.de
The Munich Life Science Cluster
- a Leading Pharma and Biotech Location
CLUSTER-MANAGEMENT
• > 250 life science companies (126 SMEs)
• > 50% of SMEs focus on Tx & Dx
• impressive drug development pipe line
• innovative platform technologies: imaging, genomics, proteomics, kinomics, etc.
• 8 excellent research institutions
• high density in hospitals, study centers
• 27 pharma companies
• 50 CROs
• 30,000 employees in the life sciences and the life science industry (SMEs: 2,850)
• > € 3 bn invested since1996
![Page 4: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/4.jpg)
www.m4.de
0 10 20 30 40 50 60
Preclinic
Phase I
Phase II
Phase III
Market
59
33
36
8
5
Number of Clinical Candidates of Biotech SMEs in the Greater Munich Area,
BioM 2010
Munich‘s Drug Development Pipeline
![Page 5: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/5.jpg)
www.m4.de
Cluster
Management
for Munich
Hospitals
in Munich
Biotech
and Pharma
in Munich
Science
in Munich
4 Strong Partners for Munich
€ 100 mn
Program
on
Personalized
Medicine
![Page 6: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/6.jpg)
www.m4.de
Structure of the m4 Program R
&D
Pro
ject
s
Stru
ctural P
rojects
SP1 – m4 Trial
Service Center
SP2 – m4
Biobank Alliance
SP3 – m4 Data
Integration System
SP4 – m4 Scouting
& Incubation
SP5 – m4
eAcademy
Board
Steering Committee
Representatives from
Academia & Industry
m4-Clustermanagement
BioM
Personalized Medicine
Targeted Therapies
Preclinical
Models
Production Processes
Associated Partners
Academia & Industry
![Page 7: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/7.jpg)
www.m4.de
Clinical Trials Phases I - III Pre Clinic Approval
eAcademy
Master of Translational Science
Executive MBA of Life Science Management
Scouting &
Incubation
special award, scouts,
targeted identification,
active incubation
Biobank Alliance
central access,
legal and ethical harmonization
highest quality standards
Trial Service Center
service and advice
phase I unit
platform service
Data Integration System
information integration
web portal
safety concept
Human Biomaterial Consulting, Recruiting
Transfer of Information
Innovation Human Capital
m4 Strategy: Establishing a Sustainable Infrastructure through Structural Projects
Translational Seed Fund: seed financing opportunities in PM (in progress)
![Page 8: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/8.jpg)
www.m4.de
m4 Scouting & Incubation
• m4 Scouting
Identification of (bio)pharmaceutical research
projects with a high innovationspotential
• m4 Mentor Circle
Professional mentoring by retired experts from
academia and industry
• m4 Award
Regional pre-seed program for innovative
research projects in the field of biomarkers
and drug development
• m4 Incubation
Assisted incubation of the m4 Award projects
![Page 9: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/9.jpg)
www.m4.de
m4 Award
• Bavarian pre-seed program for Personalized Medicine: € 8.5 Mio until 2015
• € 500,000 per project over 2 years; additional € 30,000 for coaching and special advice
• 80 short proposals received until 31st January, 2011
• 28 full length proposals received unti 30th April, 2011
•m4 Award Committee: experts from Biotech, Pharma and Venture Capital
• 5 grants awarded on 18th July, 2011
![Page 10: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/10.jpg)
www.m4.de
Winners of the First Round of the m4 Award
• K-P Hopfner, F Oduncu, G H Fey (LMU):
Triplebodies against AML
• D. Schendel, C Geiger, M Javorović (HMGU):
Individualised Dendritic Cells as Vaccines for
Patients with Hormone-resistant Prostate Cancer
• M Conrad, J A Schick (HMGU):
New Drugs for the Treatment of
Neurodegenerative Diseases
• F Hausch, M Paez-Pereda (MPI Psychiatry):
Development of FKBP51 Specific Molecules
to Treat Depression
• O Ritter (Univ. Würzburg):
Calportin as First Line Treatment of Heart Failure
![Page 11: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/11.jpg)
www.m4.de
m4 Strategy (II): Boosting Innovation through
40 R&D Projects (mostly Cooperations)
Biomarker
Identification & Validation
Companion Diagnostic
Feasibility and Benefit Market
Drug Development Clinical Trials Phase I - III Market Approval
Approval
Value Chain of Personalized Medicine
Preclinic
Validated
Test Kit
Biotech SME
Pharma/Medtech
Industry
Academia / Clinics
PM6
PM10 PM12
PM13
PM 16 PM15
T4
PM1
PM 7
PM 8
PM 17
PM 2
PM9
PM4
PM5
PM 14
T5
T10
T2
T3
T6
T12 T14
T15 T16
P2
P3
PK1
T9
T17
Focus on:
-> new targeted therapeutics
-> innovative therapy concepts
-> identification and validation of biomarkers
by molecular diagnostics and imaging
techniques
-> set up of platform technologies
main indications: oncology, cardiovascular
diseases, chronic lung diseases, autoimmune
diseases and inflammation
![Page 12: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/12.jpg)
www.m4.de
COR-1, a new Drug for the Treatment
of a Severe Form of Heart Failure
COR-1 is a cyclic peptide
which neutralizes
stimulatory autoimmune
antibodies directed against
the beta-adrenergic receptor
mimicking the effect of
natural ligands like
adrenaline and thus leading
to a chronic over-stimulation
of the receptor.
Consequently this leads to
hypertrophy and reduced
function of the heart.
• Ex vivo, COR-1 showed good
efficacy to neutralize anti ß1
receptor autoantibodies.
• In animal models, COR-1
prevented the generation of heart
failure and also reversed existing
heart failure.
• In a placebo-controlled phase
I clinical trial COR-1 was shown
to be well tolerated.
• COR-1 is now being investigated
in a phase II clinical trial; it is
administered to a subgroup of
heart failure patients who have
been stratified by a specific
diagnostic test.
COR-1 – an m4 Lighthouse Project by Corimmun
![Page 13: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/13.jpg)
www.m4.de
m4 – Evolution through Innovation
2010 1996 1984 2020
Winner in the
BioRegio Contest
Munich
Gene Center
Winner in the
Leading Edge Cluster
Competition
m4
International Cluster of Excellence
in Personalized Medicine
![Page 14: The Munich Biotech Cluster m4 Approach towards Personalised Medicine](https://reader034.fdocuments.in/reader034/viewer/2022052310/554c1816b4c905ec518b4ecf/html5/thumbnails/14.jpg)
www.m4.de
Predictive Biomarkers
- DNA/RNA-omics
- Proteomics
P4 Medicine – Healthcare of the Future
Personalized Stratification of Patients
- Herceptin
- Erbitux
- . . .
Preventive Life Style and Treatment
- Phenylketonuria
- Diabetes
- Cancer
Participatory Informed Decisions
by informed Patients
- 1000$ Genome